Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01008033 · ClinicalTrials.gov registry record · Phase 3

Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

A Phase 3 study, sponsored by Dow Pharmaceutical Sciences.

Completed
Registry status
Phase 3
Development phase
870
Enrollment target

NCT01008033 is a Phase 3 study that has completed, run by Dow Pharmaceutical Sciences. The registered enrollment target is 870 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01008033, a Phase 3 study, has completed, sponsored by Dow Pharmaceutical Sciences.

COMPLETED
Registry status
Phase 3
Development phase
870 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the safety and efficacy of topical application of IDP-108 versus vehicle in treating patients with onychomycosis.

Interventions

  • DRUG Vehicle
  • DRUG IDP-108

Trial Details

FieldValue
Enrollment Target 870 participants
Start Date 2009-11
Est. Completion 2011-12
Phase Phase 3

Sponsor

Dow Pharmaceutical Sciences

7 total trials

What the Registry Record Tells You About NCT01008033

The ClinicalTrials.gov registry entry for NCT01008033 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 870 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dow Pharmaceutical Sciences, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.

NCT01008033 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01008033 about?

NCT01008033 is a clinical study titled "Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis". The purpose of this study is to evaluate the safety and efficacy of topical application of IDP-108 versus vehicle in treating patients with onychomycosis.

What is the current status of trial NCT01008033?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 870 participants. The study started on 2009-11. Estimated completion is 2011-12.

What interventions are being tested in trial NCT01008033?

The interventions under investigation include: Vehicle (DRUG), IDP-108 (DRUG).

Who is sponsoring clinical trial NCT01008033?

This trial is sponsored by Dow Pharmaceutical Sciences, which has 7 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.